At a glance

ClinicalIndex Comparison Record

Phase 4Completed· 217 enrolled

Drug / intervention

Desloratadine +1 moredrug

Likely dose

Desloratadine 2.5 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00779116

NCT00779116Phase 4Completed

Compare CT.gov

A Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications

Organon and Co·interventional·Posted Oct 24, 2008·Updated Feb 9, 2022

In Brief

A Phase 4 clinical trial evaluating Desloratadine and Zyrtec® (cetirizine) for Allergies. Completed, enrolled 217 participants.

Detailed Summary

This was a randomized, open-label, 2-way cross-over study, comparing desloratadine RediTab 2.5 mg to a marketed chewable antihistamine oral medication (Zyrtec® 5 mg Chewable Tablet). Subject preference for one product or the other was determined. Acceptability of product attributes (Taste and Feeling in the Mouth) was rated using a "smile" face scale.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsAllergies

Countries--

Collaborators--

Timeline

Phase 4CompletedFinished

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartSep 2005

Primary CompletionOct 2005

First PostedOct 2008

TodayJul 2026

First PostedOct 24, 2008

Enrollment StartSep 1, 2005

Primary CompletionOct 1, 2005

TodayJul 2, 2026

Enrollment to primary: 1 monthPosted 17.7 years ago

Interventions

Desloratadinedrug

SCH 34117: desloratadine RediTabs, 1 tablet (2.5 mg), oral administration, single dose, single day

Zyrtec® (cetirizine)drug

Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single dose, single day